Recurrent Melanoma Completed Phase 2 Trials for Aldesleukin (DB00041)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01258855Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryTreatment
NCT00005949Vaccine Plus Interleukin-2 in Treating Patients With Advanced MelanomaTreatment